Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nα‑[(2S)‑2‑{[(S)‑[(1S)‑1‑{[(Benzyloxy)carbonyl]amino}‑2‑phenylethyl](hydroxy)phosphoryl]methyl}‑5‑phenylpentanoyl]–L–tryptophanamide is a synthetic small molecule belonging to the class of n-acyl-alpha amino acids and derivatives[1][3]. It is an experimental compound, not approved for clinical use, and has been studied primarily as a research tool. The molecule features a benzyloxycarbonyl-protected amino group, phenylethyl and tryptophan moieties, and a hydroxyphosphinyl group. While its precise mechanism of action in humans is not fully characterized in public sources, it has structural similarity to retro-thiorphan analogues that are known inhibitors of certain metalloproteases such as neutral endopeptidase (NEP), suggesting potential activity as an enzyme inhibitor[8]. No clinical indications or advanced development status are reported.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Nα-[(2S)-2-{[(S)-[(1S)-1-{[(Benzyloxy)carbonyl]amino}-2-phenylethyl](hydroxy)phosphoryl]methyl}-5-phenylpentanoyl]-L-tryptophanamide.